Skip to main navigation Skip to search Skip to main content

Heavy-chain antibody targeting of CD38 NAD+ hydrolase ectoenzyme to prevent fibrosis in multiple organs

  • Bo Shi
  • , Asif Amin
  • , Pranjali Dalvi
  • , Wenxia Wang
  • , Nicholas Lukacs
  • , Li Kai
  • , Paul Cheresh
  • , Thais R. Peclat
  • , Claudia C. Chini
  • , Eduardo N. Chini
  • , Wim van Schooten
  • , John Varga

Research output: Contribution to journal › Article › peer-review

Abstract

The functionally pleiotropic ectoenzyme CD38 is a glycohydrolase widely expressed on immune and non-hematopoietic cells. By converting NAD+ to ADP-ribose and nicotinamide, CD38 governs organismal NAD+ homeostasis and the activity of NAD+-dependent cellular enzymes. CD38 has emerged as a major driver of age-related NAD+ decline underlying adverse metabolic states, frailty and reduced health span. CD38 is upregulated in systemic sclerosis (SSc), a chronic disease characterized by fibrosis in multiple organs. We sought to test the hypothesis that inhibition of the CD38 ecto-enzymatic activity using a heavy-chain monoclonal antibody Ab68 will, via augmenting organismal NAD+, prevent fibrosis in a mouse model of SSc characterized by NAD+ depletion. Here we show that treatment of mice with a non-cytotoxic heavy-chain antibody that selectively inhibits CD38 ectoenzyme resulted in NAD+ boosting that was associated with significant protection from fibrosis in multiple organs. These findings suggest that targeted inhibition of CD38 ecto-enzymatic activity could be a potential pharmacological approach for SSc fibrosis treatment.

Original languageEnglish (US)
Article number22085
JournalScientific reports
Volume13
Issue number1
DOIs
StatePublished - Dec 2023

ASJC Scopus subject areas

  • General

Fingerprint

Dive into the research topics of 'Heavy-chain antibody targeting of CD38 NAD+ hydrolase ectoenzyme to prevent fibrosis in multiple organs'. Together they form a unique fingerprint.

Cite this